Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABOUND.2L nab-paclitaxel with or without CC-486 in second-line nonsquamous NSCLC
NL-OMON41094Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Oct 2014
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing nab-paclitaxel + CC-486 with nab-paclitaxel monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Oct 2014; status: withdrawn.
02
Drugs
paclitaxelCC-486
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON41094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41094.